TABLE 2.

Hazard ratios (HR) for overall survival in the population with a favorable prognosis.

		Intervention [HR (95% CI)]
		CAB + NIV	AXY + PEM	LEN + PEM	SUN
Comparator	CAB + NIV		1.23 (0.43; 2.2)	1.26 (0.30; 2.56)	1.02 (0.45; 1.68)
	AXY + PEM	0.95 (0.33; 1.71)		1.08 (0.32; 2.06)	0.88 (0.51; 1.26)
	LEN + PEM	1.01 (0.23; 2.05)	1.12 (0.33; 2.13)		0.93 (0.34; 1.65)
	SUN	1.08 (0.47; 1.80)	1.20 (0.72; 1.74)	1.23 (0.45; 2.18)

The values in each cell represent the relative treatment effect for the intervention on the top when compared to the intervention on the left. Green suggests a relative treatment benefit (light green a nonsignificant benefit, and dark green a significant benefit). Red suggests a relative treatment harm (light red a nonsignificant harm, and dark red a significant harm).AXY, axitinib; CAB, cabozantinib; IPI, ipilimumab; LEN, lenvatinib; NIV, nivolumab; PEM, pembrolizumab; SUN, sunitinib